ArticleAmerican journal of translational research2026
Predictive value of endothelial activation and stress index for acute kidney injury in hospitalized patients with multiple myeloma.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the predictive value of Endothelial Activation and Stress Index (EASIX) for acute kidney injury (AKI) in hospitalized patients with multiple myeloma (MM).
methodsThis retrospective study included 352 MM patients admitted to our hospital between January 2020 and December 2024. Patients were divided into a training set (n = 248) and a validation set (n = 104) using a time-based split. Patients were further classified into AKI (training n = 52, validation n = 22) and non-AKI groups (training n = 196, validation n = 82) according to occurrence of AKI during hospitalization. Factors associated with the development of AKI in MM patients were identified using logistic regression analysis. The predictive performance of EASIX for AKI was assessed by receiver operating characteristic (ROC) curve analysis.
resultsIn the training set, binary logistic regression analysis revealed that EASIX, International Staging System (ISS) stage, and bortezomib-lenalidomide-dexamethasone (VRD) chemotherapy regimen were independent factors influencing the development of AKI in MM patients during hospitalization (all
conclusionEASIX holds promise in predicting AKI in hospitalized MM patients, supporting its potential use in risk stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.